• 1
    UNAIDS (2006). Report on the Global AIDS Epidemic. UNAIDS, Geneva.
  • 2
    Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 7383.
  • 3
    Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73: 125363.
  • 4
    Gupta K, Klasse PJ. How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 2006; 3: e79.
  • 5
    Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003; 9: 84752.
  • 6
    Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1: 2534.
  • 7
    Zaitseva M, Blauvelt A, Lee S et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 1997; 3: 136975.
  • 8
    Sugaya M, Lore K, Koup RA, Douek DC, Blauvelt A. HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. J Immunol 2004; 172: 221924.
  • 9
    Kavanagh DG, Bhardwaj N. A division of labor: DC subsets and HIV receptor diversity. Nat Immunol 2002; 3: 8913.
  • 10
    Turville SG, Cameron PU, Handley A et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002; 3: 97583.
  • 11
    Kawamura T, Cohen SS, Borris DL et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000; 192: 1491500.
  • 12
    Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100: 58797.
  • 13
    Wilflingseder D, Banki Z, Dierich MP, Stoiber H. Mechanisms promoting dendritic cell-mediated transmission of HIV. Mol Immunol 2005; 42: 22937.
  • 14
    Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J Leukoc Biol 2003; 74: 7108.
  • 15
    Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 36777.
  • 16
    Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 117981.
  • 17
    Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306: 4857.
  • 18
    Meng G, Wei X, Wu X et al. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med 2002; 8: 1506.
  • 19
    Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3: 427.
  • 20
    Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5: 78392.
  • 21
    Miller CJ, Li Q, Abel K et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79: 921727.
  • 22
    Miller CJ, Alexander NJ, Sutjipto S et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol 1989; 63: 427784.
  • 23
    Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997; 146: 3507.
  • 24
    Gray RH, Wawer MJ, Brookmeyer R et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 114953.
  • 25
    Wawer MJ, Gray RH, Sewankambo NK et al. Rates of HIV-1 transmission per coital act, by stage of HIV infection, in Rakai, Uganda. J Infect Dis 2005; 191: 14039.
  • 26
    Kresge KJ. HIV-1 prevention picks up momentum: Discussion of microbicides, vaccines, and other new prevention technologies tops the bill at international AIDS conference. IAVI Rep 2006; 10: 7-8.
  • 27
    Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5: 87103.
  • 28
    Shacklett BL. Understanding the ‘‘lucky few’’: the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006; 3: 2631.
  • 29
    Clerici M, Clark EA, Polacino P et al. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS 1994; 8: 13915.
  • 30
    Pantaleo G, Menzo S, Vaccarezza M et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 20916.
  • 31
    Pilgrim AK, Pantaleo G, Cohen OJ et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997; 176: 92432.
  • 32
    Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 2018.
  • 33
    Guevara H, Casseb J, Zijenah LS et al. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr 2002; 29: 43540.
  • 34
    Lathey JL, Tsou J, Brinker K, Hsia K, Meyer WA Jr, Spector SA. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J Infect Dis 1999; 180: 34450.
  • 35
    Scarlatti G, Albert J, Rossi P et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993; 168: 20710.
  • 36
    Mascola JR, D'Souza P, Gilbert P et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79: 101037.
  • 37
    Mestecky J, Jackson S, Moldoveanu Z et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20: 97288.
  • 38
    Clerici M, Barassi C, Devito C et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16: 173141.
  • 39
    Dorrell L, Hessell AJ, Wang M et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000; 14: 111722.
  • 40
    Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001; 15: 4312.
  • 41
    Devito C, Broliden K, Kaul R et al. Mucosal and plasma IgA from HIV-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165: 51706.
  • 42
    Devito C, Hinkula J, Kaul R et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV isolate. AIDS 2000; 14: 191720.
  • 43
    Devito C, Hinkula J, Kaul R et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002; 30: 41320.
  • 44
    Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 30712.
  • 45
    Wilson DB, Wyatt DP. Patterns of lectin binding during mammalian neurogenesis. J Anat 1995; 186: 20916.
  • 46
    Weis WI. Cell-surface carbohydrate recognition by animal and viral lectins. Curr Opin Struct Biol 1997; 7: 62430.
  • 47
    Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 2006.
  • 48
    Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11: 61522.
  • 49
    Kaul R, Kimani J, Nagelkerke NJ et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291: 255562.
  • 50
    Cameron P, Pope M, Granelli-Piperno A, Steinman RM. Dendritic cells and the replication of HIV-1. J Leukoc Biol 1996; 59: 15871.
  • 51
    Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol 2006; 6: 85968.
  • 52
    Söderlund J, Hirbod T, Smed-Sörensen A et al. Plasma and mucosal fluid from HIV-1 infected patients but not from HIV-1 exposed uninfected subjects prevent HIV-1 exposed DC from infecting other target cells. AIDS Res Hum Retroviruses 2007; 23: 1016.
  • 53
    Kondera-Anasz Z, Sikora J, Mielczarek-Palacz A. Leukemia inhibitory factor: an important regulator of endometrial function. Am J Reprod Immunol 2004; 52: 97105.
  • 54
    Moriyama A, Shimoya K, Ogata I et al. Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Hum Reprod 1999; 5: 65661.
  • 55
    King AE, Fleming DC, Critchley HO, Kelly RW. Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium. J Reprod Immunol 2003; 59: 116.
  • 56
    Fleming DC, King AE, Williams AR, Critchley HO, Kelly RW. Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril 2003; 79: 85663.
  • 57
    Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307: 143440.
  • 58
    Heeney JL, Dalgleish AG, Weiss RA. Origins of HIV and the evolution of resistance to AIDS. Science 2006; 313: 4626.
  • 59
    Iqbal SM, Ball TB, Kimani J et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005; 192: 72838.
  • 60
    Franken C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989; 37: 4938.
  • 61
    McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 45664.
  • 62
    McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90: 11419.
  • 63
    Iqbal SM. Trappin-2: Discovery of a Novel Inhibitor of HIV-1 Highly Elevated in HIV-1-Resistant Sex Workers. Toronto, Canada: XVI International AIDS conference, 2006.
  • 64
    Stolzenberg ED, Anderson GM, Ackermann MR, Whitlock RH, Zasloff M. Epithelial antibiotic induced in states of disease. Proc Natl Acad Sci USA 1997; 94: 868690.
  • 65
    Zhao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396: 31922.
  • 66
    Trabattoni D, Caputo SL, Maffeis G et al. Human alpha Defensin in HIV-Exposed But Uninfected Individuals. J Acquir Immune Defic Syndr 2004; 35: 45563.
  • 67
    Wira CR, Fahey JV. The innate immune system: gatekeeper to the female reproductive tract. Immunology 2004; 111: 1315.
  • 68
    Quinones-Mateu ME, Lederman MM, Feng Z et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17: F3948.
  • 69
    Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3–a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006; 177: 7826.
  • 70
    Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. The endogenous host defence peptide LL-37 inhibits HIV-infection. Current HIV-Research, In Press, 2007.
  • 71
    Biron CA. Initial and innate responses to viral infections–pattern setting in immunity or disease. Curr Opin Microbiol 1999; 2: 37481.
  • 72
    Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 22764.
  • 73
    Soumelis V, Scott I, Gheyas F et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98: 90612.
  • 74
    Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006; 120: 13846.
  • 75
    Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 84853.
  • 76
    Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99103.
  • 77
    Mariani R, Chen D, Schrofelbauer B et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114: 2131.
  • 78
    Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006; 203: 4146.
  • 79
    Piacentini L, Biasin M, Lo Caputo S et al. Upregulation of APOBEC 3G and 3F in Cervical Biopsies of Exposed Uninfected Individuals. Toronto, Canada: XVI International AIDS conference, 2006.
  • 80
    Ganesh L, Burstein E, Guha-Niyogi A et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003; 426: 8537.
  • 81
    Hirbod T, Nilsson J, Andersson S et al. Upregulation of Interferon-alpha and RANTES in the cervix of HIV-1 seronegative women with high-risk behavior. J AIDS 2006; 43: 13743.
  • 82
    Nilsson J, Kinloch-de-Loes S, Granarth A, Sonnerborg A, Goh LE, Andersson J. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV-1 infection. AIDS 2007; 21: 56574.
  • 83
    Herbeuval JP, Hardy AW, Boasso A et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2005; 102: 139749.
  • 84
    Mackewicz CE, Ortega H, Levy JA. Effect of cytokines on HIV-1 replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol 1994; 153: 32943.
  • 85
    Mackewicz CE, Blackbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995; 92: 230812.
  • 86
    McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV-1. Nature 2001; 410: 9807.
  • 87
    Mazzoli S, Trabattoni D, Lo Caputo S et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3: 12507.
  • 88
    Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, Oksenhendler E. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest 1994; 93: 12937.
  • 89
    Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 5964.
  • 90
    Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102: 175865.
  • 91
    Kaul R, Plummer FA, Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164: 160211.
  • 92
    Kaul R, Rowland-Jones SL, Kimani J et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001; 79: 313.
  • 93
    Kaul R, Rowland-Jones SL, Kimani J et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001; 107: 3419.
  • 94
    Kaul R, Dong T, Plummer FA et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107: 130310.
  • 95
    Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 47819.
  • 96
    Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 7225.
  • 97
    Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 12403.
  • 98
    O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36: 56574.
  • 99
    Shrestha S, Strathdee SA, Galai N et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006; 193: 1626.
  • 100
    Mitchell EA, Bergmeier LA, Doyle C et al. Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Eur J Immunol 1998; 28: 306674.
  • 101
    Li Q, Duan L, Estes JD et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434: 114852.
  • 102
    Zhang Z, Schuler T, Zupancic M et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286: 13537.
  • 103
    Baig J, Levy DB, McKay PF et al. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 2002; 76: 1148490.
  • 104
    Kozlowski PA, Neutra MR. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003; 3: 21728.
  • 105
    Albu DI, Jones-Trower A, Woron AM, Stellrecht K, Broder CC, Metzger DW. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol 2003; 77: 558997.
  • 106
    Marinaro M, Riccomi A, Rappuoli R et al. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine 2003; 21: 397281.
  • 107
    Devito C, Zuber B, Schroder U et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 2004; 173: 707889.
  • 108
    Bergmeier LA, Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 2006; 19: 218.